USA - NASDAQ:BGMS - US23254L8761 - Common Stock
The current stock price of BGMS is 5.15 USD.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.83 | 389.72B | ||
AMGN | AMGEN INC | 12.52 | 146.96B | ||
GILD | GILEAD SCIENCES INC | 14.48 | 139.09B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.77 | 98.90B | ||
REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.77B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.51B | ||
ARGX | ARGENX SE - ADR | 76.77 | 43.55B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.71 | 38.76B | ||
INSM | INSMED INC | N/A | 28.96B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
NTRA | NATERA INC | N/A | 22.37B | ||
BIIB | BIOGEN INC | 8.58 | 20.14B |
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
BIO GREEN MED SOLUTION INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY US
Employees: 0
Phone: 19085177330
The current stock price of BGMS is 5.15 USD. The price increased by 8.65% in the last trading session.
The exchange symbol of BIO GREEN MED SOLUTION INC is BGMS and it is listed on the Nasdaq exchange.
BGMS stock is listed on the Nasdaq exchange.
BIO GREEN MED SOLUTION INC (BGMS) has a market capitalization of 11.54M USD. This makes BGMS a Nano Cap stock.
BIO GREEN MED SOLUTION INC (BGMS) currently has 0 employees.
The Revenue of BIO GREEN MED SOLUTION INC (BGMS) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the BGMS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BGMS does not pay a dividend.
BIO GREEN MED SOLUTION INC (BGMS) will report earnings on 2025-11-10.
BIO GREEN MED SOLUTION INC (BGMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-122.02).
ChartMill assigns a technical rating of 2 / 10 to BGMS.
Over the last trailing twelve months BGMS reported a non-GAAP Earnings per Share(EPS) of -122.02. The EPS increased by 96.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -146.06% | ||
ROE | -177.03% | ||
Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for BGMS